Research Analysts Set Expectations for Vaxcyte Q3 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Stock analysts at Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of Vaxcyte in a report released on Wednesday, May 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($1.22) per share for the quarter, up from their previous estimate of ($1.23). The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.09) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.75) EPS and FY2028 earnings at ($4.83) EPS.

PCVX has been the topic of several other reports. Cantor Fitzgerald began coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They set an “overweight” rating on the stock. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Bank of America cut their price target on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $136.50.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $31.16 on Monday. The firm’s 50-day simple moving average is $46.66 and its 200-day simple moving average is $74.19. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $121.06. The firm has a market cap of $4.02 billion, a P/E ratio of -6.77 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the business posted ($0.85) EPS.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently modified their holdings of PCVX. Capital Research Global Investors raised its stake in shares of Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after buying an additional 1,312,302 shares during the last quarter. Norges Bank bought a new stake in shares of Vaxcyte during the fourth quarter worth approximately $90,069,000. Vanguard Group Inc. raised its stake in shares of Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after buying an additional 521,204 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of Vaxcyte by 57.3% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company’s stock worth $116,469,000 after buying an additional 518,255 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of Vaxcyte during the fourth quarter worth approximately $39,846,000. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.